Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 47 results
A blood pressure cuff and stethoscope in a clinical setting

May 1, 2026

Cardio Diagnostics Holdings (CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights

Cardio Diagnostics Holdings (CDIO) is taking significant steps to combat heart disease by leveraging AI and biomarker analysis for early detection and personalized insights.Cardiovascular disease remains a critical global health issue, imposing severe burdens on individuals and healthcare systems alike. Cardio Diagnostics Holdings aims to mitigate this impact by developing a platform that utilizes artificial intelligence alongside epigenetic and genetic biomarkers. This innovative approach allow
A flat design of a blood droplet and biomarker icon representing cardiovascular diagnostics.

May 1, 2026

Cardio Diagnostics Holdings (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights

Cardio Diagnostics Holdings is leveraging artificial intelligence and biomarker analysis to enhance early detection of cardiovascular disease, a leading global health concern.The burden of cardiovascular disease is significant, affecting millions and imposing heavy costs on healthcare systems. Cardio Diagnostics Holdings (NASDAQ: CDIO) is addressing this urgent need by developing a unique platform that integrates AI with multi-omic biomarker analysis. This innovation aims to provide personalized
A minimalist illustration of a retina and circular RNA strand for Alzheimer's detection.

Apr 30, 2026

Circular Genomics and Vitazi.ai Forge Strategic Alliance to Develop First-in-Class Multimodal Workflow for Early Alzheimer's Detection

Circular Genomics and Vitazi.ai have announced a strategic partnership aimed at revolutionizing early Alzheimer's disease detection through a multimodal workflow that integrates AI-powered retinal imaging with circular RNA biomarkers.This collaboration seeks to address significant gaps in the current diagnostic landscape for Alzheimer's, where many patients are diagnosed only after symptoms have progressed. The new approach combines non-invasive retinal imaging analytics from Vitazi.ai with Circ
A minimalist representation of retinal imaging and RNA biomarkers for Alzheimer's detection.

Apr 29, 2026

New Partnership Aims to Improve Early Alzheimer’s Disease Detection

A strategic partnership between Circular Genomics and Vitazi.ai aims to enhance early detection of Alzheimer’s disease through innovative diagnostic technologies.The collaboration seeks to merge artificial intelligence-driven retinal imaging with blood-based RNA biomarkers to identify individuals at risk for Alzheimer’s. This partnership addresses existing gaps in early-stage patient identification and aims to create a comprehensive diagnostic framework.The proposed workflow involves a two-step
Flat illustration of a DNA strand and AI molecule

Apr 29, 2026

$2.25 Billion DNA Editing Deal Signals Why AI Training Is Becoming Essential in Biotech

The recent $2.25 billion partnership between Profluent and Eli Lilly underscores the growing importance of AI in biotechnology, particularly in the realm of DNA editing.This collaboration aims to develop AI-designed recombinases—enzymes capable of precisely altering larger DNA sequences, addressing complex genetic diseases that traditional editing methods struggle to treat. By harnessing AI, the partnership seeks to enhance treatment options for rare diseases and inherited disorders, potentially
A test tube with a colorful liquid on a lab bench, symbolizing genetic medicine.

Apr 29, 2026

Profluent, Eli Lilly Strike $2.25B AI-Driven Genetic Medicine Pact for Precision DNA Editing

Profluent and Eli Lilly have entered a significant multi-program collaboration valued at up to $2.25 billion, focusing on advanced AI-driven genetic medicine aimed at precision DNA editing.The partnership centers around Profluent's innovative use of AI to develop recombinases, which are enzymes designed for kilobase-scale DNA editing. This technology is particularly important for addressing genetic diseases characterized by multiple mutations, a challenge that traditional methods like CRISPR str
A DNA editing tool on a lab table with scientific books in the background.

Apr 28, 2026

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

Lilly has announced a significant partnership with AI-driven Profluent Bio, aiming to advance genetic medicine through a deal potentially worth up to $2.25 billion. The collaboration focuses on developing innovative DNA editing tools to address genetic conditions that currently lack effective treatments.The partnership will leverage Profluent's AI models to create site-specific recombinases—enzymes capable of precise DNA manipulation. Lilly will have exclusive rights to license and advance selec
A close-up of a DNA strand on a lab bench in a biotechnology lab.

Apr 28, 2026

AI start-up Profluent nabs Lilly as first big pharma partner

AI start-up Profluent has formed a significant partnership with Eli Lilly, valued at up to $2.25 billion, to advance gene-editing therapies. Founded in 2022, Profluent has garnered attention for its innovative technology that enables the insertion of entire genes into DNA, surpassing the localized editing capabilities of methods like CRISPR/Cas9. This collaboration aims to leverage Profluent's AI models for developing recombinase editors that can insert extensive DNA sequences at specific genomi
A minimalist representation of a genome sequence in a dark color scheme.

Apr 28, 2026

Europe AI in Genomics Market Size, Share, & Growth, 2034

The European AI in Genomics market is rapidly expanding, projected to grow from $448.48 million in 2025 to an impressive $9,568.11 million by 2034, with a remarkable compound annual growth rate (CAGR) of 40.5% from 2026 to 2034.This growth is driven by the integration of artificial intelligence technologies, such as machine learning and natural language processing, into genomics. These technologies are essential for analyzing the vast amounts of data generated by next-generation sequencing, faci
A minimalist representation of a single cell with surrounding data points.

Apr 27, 2026

AI in single-cell analysis: solving the interpretation gap

AI is increasingly becoming a key player in single-cell analysis, particularly in addressing the challenges of data interpretation in drug discovery.Single-cell omics is revolutionizing drug discovery by allowing researchers to analyze biological systems at an unprecedented resolution. However, the growing complexity of the data presents significant interpretative challenges. Parashar Dhapola, co-founder of Nygen Analytics, emphasizes that converting vast amounts of raw single-cell data into act
A flat illustration of a DNA strand

Apr 26, 2026

Did DRAGEN v4.5’s AI Genomics Push Just Shift Illumina’s (ILMN) Investment Narrative?

Illumina's recent release of DRAGEN v4.5 marks a significant advancement in genomic analysis, integrating enhanced accuracy and machine-learning capabilities into its software platform. This upgrade not only supports oncology applications but also strengthens multiomic analysis, including oncovirus detection, positioning Illumina as a key player in large-scale clinical genomics.The partnership with the Center for Data-Driven Discovery in Biomedicine aims to process 100,000 pediatric whole genome